Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Research Grant, 2018
    Functional Fine-mapping of LRRK2 Locus

    Study Rationale:
    Genetic studies for Parkinson's disease have indicated that variants of the LRRK2 gene are associated with increased risk of Parkinson's disease. However, we still know very little...

  • Research Grant, 2018
    Optimization of Probe-ELISA Parkin Activity Assay

    Promising Outcomes of Original Grant:
    Certain forms of Parkinson's are due to defects in a cellular regulatory node known as the PINK1-Parkin pathway. With previous funding from MJFF, we sought to...

  • Research Grant, 2018
    Evaluating the Therapeutic Potential of the Systemic Antagonism of Dopamine Receptor D3

    Promising Outcomes of Original Grant:
    Parkinson's disease involves toxic forms of certain proteins (e.g., alpha-synuclein) in the brain, which trigger an immune response driven by inflammatory...

  • Research Grant, 2018
    Structure-Based Design of Small-Molecule Activators of Parkin

    Promising Outcomes of Original Grant:
    The protein Parkin requires activation by another enzyme called PINK1. With previous MJFF funding, we identified a new class of chemical fragments that could be...

  • Target Advancement Program, 2018
    Validating Astrocyte-produced Protein GDF15 as a Novel Neuroprotective Therapy

    Study Rationale:
    In Parkinson's disease (PD), death of dopamine-producing brain cells takes place mainly the substantia nigra pars compacta (SN) but not in the neighboring ventral tegmental area (VTA)...

  • Target Advancement Program, 2018
    Testing the Ability of Clenbuterol to Prevent or Modify the Course of Parkinson's Disease

    Study Rationale:
    Protein alpha-synuclein clumps in the brains of people with Parkinson's disease (PD), forming Lewy bodies. Recent studies have suggested that beta-2 adrenoreceptor agonists -- drugs...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.